Navigation Links
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet(R)
Date:9/30/2009

PITTSBURGH, Sept. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg.

Carbidopa and Levodopa Tablets are the generic version of Bristol Myers Squibb's Parkinson's treatment Sinemet®, 10mg/100mg, 25mg/100mg and 25mg/250 mg. For the 12 months ending June 30, 2009, Carbidopa and Levodopa tablets had U.S. sales of approximately $79 million for the same strengths, according to IMS Health. Mylan has launched this product.

Currently, Mylan has 123 ANDAs pending FDA approval representing $86.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $17.4 billion in annual brand sales, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
2. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
3. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
4. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
5. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
6. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
7. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
8. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
9. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
10. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
11. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Financial Highlights f or the ... : Revenues increased 58.1% to $24.2 million ... Net income rose 73.6% to $13.4 million, representing a net margin of 55.5% ... " ) increased to $0.80; Diluted EPS increased to $0.79 ...
... EMERYVILLE, Calif., March 28, 2011 Bionovo, Inc. (Nasdaq: ... and development of safe and effective treatments for women,s health ... Phase 1 clinical trial testing the safety of two doses ... hot flushes (study # MF101-008), also known as "menopausal hot ...
Cached Medicine Technology:Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 2Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 3Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 4Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 5Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 6Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 7Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 8Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 9Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 2Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 3
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
(Date:7/8/2014)... enjoy similar longevity and cardiovascular health as other healthy ... the American Journal of Transplantation . The findings ... and the transplant professionals caring for them. , Over ... aged 55 years and older has become more common. ... heart disease, the removal of a kidney could make ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
(Date:7/8/2014)... Hand hygiene rates were found to be three times ... when there were no auditors present, according to a ... , The study, titled, "Quantification of the Hawthorne effect ... system: a retrospective cohort study," published today on-line in ... first author Dr. Jocelyn Srigley, who did the study ...
(Date:7/8/2014)... biomarker that could give expecting mothers and their doctors ... a pregnant woman may develop preeclampsia, at least as ... is a cardiovascular disorder generally occurring late in pregnancy ... and potentially lifelong risks to both mother and baby. ... urine, and is typically diagnosed in the late second ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... the NFL,s,Chicago Bears will visit hospitalized veterans Tuesday, November ... part of the Disabled American,Veterans (DAV) Celebrity Entertainment Program., ... 2:30 p.m., to honor,veterans for serving our nation by ... day for those who have sacrificed,so much for the ...
... Certification ... Criteria -, ... (CCHIT(sm)) today announced that the,Eclypsis Corporation(R) (Nasdaq: ECLP ), The ... Sunrise Clinical Manager(TM),is CCHIT Certified(sm), and meets the Commission,s newly launched ...
... Care Awareness Week, WASHINGTON, Nov. 5 ... coverage for long-term care expenses,according to new survey ... The survey found that many Baby Boomers have ... have not thought about,long-term care insurance. (Logo: ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today ... 2b clinical trial of the investigational drug, Albuferon ... patients with genotype 1 chronic hepatitis C. The ... groups reported fewer missed days of work and ...
... AEDs available in communities could save hundreds of lives, ... Compared with cardiopulmonary resuscitation (CPR) alone, bystander use of ... than doubles a person,s chances of surviving cardiac arrest ... , The researchers analyzed the cases of ...
... (ACP) today renewed its call on Congress to replace the ... effect Jan. 1 with at least two years of positive ... not make the problem worse in future years. The ... students reacted to the final physician fee schedule published late ...
Cached Medicine News:Health News:Eclipsys Sunrise Acute Care Receives CCHIT Certification 2Health News:Eclipsys Sunrise Acute Care Receives CCHIT Certification 3Health News:Eclipsys Sunrise Acute Care Receives CCHIT Certification 4Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 2Health News:New Survey Finds One in Four Baby Boomers Erroneously Believe They Have Coverage for Long-Term Care Expenses 3Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 2Health News:HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C 3Health News:CPR, Defibrillator Combo Boosts Cardiac Incident Survival 2Health News:Congress called on to replace 'devastating' cuts in Medicare reimbursements by ACP 2
... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
Plastic Citrate Tube, .109M / 3.2%...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: